Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors
Open Access
- 16 February 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (2), e4482
- https://doi.org/10.1371/journal.pone.0004482
Abstract
SMARCB1 is deleted in rhabdoid tumor, an aggressive paediatric malignancy affecting the kidney and CNS. We hypothesized that the oncogenic pathway in rhabdoid tumors involved epigenetic silencing of key cell cycle regulators as a consequence of altered chromatin-remodelling, attributable to loss of SMARCB1, and that this hypothesis if proven could provide a biological rationale for testing epigenetic therapies in this disease. We used an inducible expression system to show that the imprinted cell cycle inhibitor CDKN1C is a downstream target for SMARCB1 and is transcriptionally activated by increased histone H3 and H4 acetylation at the promoter. We also show that CDKN1C expression induces cell cycle arrest, CDKN1C knockdown with siRNA is associated with increased proliferation, and is able to compete against the anti-proliferative effect of restored SMARCB1 expression. The histone deacetylase inhibitor (HDACi), Romidepsin, specifically restored CDKN1C expression in rhabdoid tumor cells through promoter histone H3 and H4 acetylation, recapitulating the effect of SMARCB1 on CDKNIC allelic expression, and induced cell cycle arrest in G401 and STM91-01 rhabdoid tumor cell lines. CDKN1C expression was also shown to be generally absent in clinical specimens of rhabdoid tumor, however CDKN1A and CDKN1B expression persisted. Our observations suggest that maintenance of CDKN1C expression plays a critical role in preventing rhabdoid tumor growth. Significantly, we report for the first time, parallels between the molecular pathways of SMARCB1 restoration and Romidepsin treatment, and demonstrate a biological basis for the further exploration of histone deacetylase inhibitors as relevant therapeutic reagents in the treatment of rhabdoid tumor.Keywords
This publication has 52 references indexed in Scilit:
- Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexesNature Genetics, 2004
- Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1Human Molecular Genetics, 2001
- Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in MiceMolecular and Cellular Biology, 2001
- The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppressionEMBO Reports, 2000
- Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in miceProceedings of the National Academy of Sciences, 2000
- Expression of p57KIP2 Potently Blocks the Growth of Human Astrocytomas and Induces Cell SenescenceThe American Journal of Pathology, 2000
- Analysis of CDKN1C in Beckwith Wiedemann SyndromeHuman Mutation, 2000
- Mutations of the hSNF5/INI1 Gene in Renal Rhabdoid Tumors With Second Primary Brain TumorsJNCI Journal of the National Cancer Institute, 2000
- Familial Posterior Fossa Brain Tumors of Infancy Secondary to Germline Mutation of the hSNF5 GeneAmerican Journal of Human Genetics, 2000
- Spectrum of hSNF5IINI1 Somatic Mutations in Human Cancer and Genotype-Phenotype CorrelationsHuman Molecular Genetics, 1999